For research and education only · Not reviewed by a medical professional · Disclaimer

Peptide encyclopedia/ Melanotan II
Illustration for Melanotan II

THE PEPSRADAR ENCYCLOPEDIA

Melanotan II

Melanocortin-related pigmentation research

Research topics · Sources checked 2026-10-04

Read the studies ↓Explore the molecule ↗

Corrected October 11, 2026: We removed upcoming-trial records that turned out not to be real studies (fake ClinicalTrials.gov registrations). Corrections log

Melanotan II · KEY FACTS

Content updated · how dates work

Saved peptides

What is Melanotan II?

Melanotan II is a synthetic, ring-shaped analog of alpha-MSH that darkens skin by acting on melanocortin receptors throughout the body. About 23 people were given it in small studies from 1996 to 2000; it was never approved, and case reports link it to changing moles, melanoma and other serious harms. It is a different drug from the approved afamelanotide (Scenesse) and bremelanotide (Vyleesi).

Video overview · 3:31

Melanotan II, the "Barbie Drug": Is It a Safe Way to Tan? What the Research and Case Reports Show

How Melanotan II differs from its two approved relatives, the tiny 1990s trials, case reports of changing moles, melanoma and other harms, regulator warnings, and why it was never approved.

Narrated with an AI voice from this profile's sources; education only, no dosing.

Read the transcript

Melanotan II is sold online as a tanning injection or nasal spray, and it's sometimes called the Barbie drug. It was developed as a medicine in the 1990s, but it was never approved, and regulators on several continents warn against it. Here's what's actually known.

Melanotan II is a ring-shaped, lab-made copy of alpha-MSH, the hormone that darkens skin, built at the University of Arizona. Don't confuse it with its relatives. Melanotan one became Scenesse, approved in 2019 for a rare light-sensitivity disease. And a related peptide, bremelanotide, became Vyleesi, approved in 2019 for low sexual desire in women before menopause.

Melanotan II switches on melanocortin receptors all over the body, not just in skin. One receptor darkens the skin. Others affect sexual arousal and, in mice, appetite. That lack of focus is why tanning comes with side effects like nausea and unwanted erections.

The human research is tiny. In a 1996 pilot, two of three men tanned, with nausea, fatigue, yawning and spontaneous erections. Then two small trials tested it for erectile dysfunction: seventeen of twenty men had erections, but in one trial, severe nausea followed four of nineteen injections. It was never developed further.

Most of what's known since then comes from case reports of people using it on their own. They describe new or darkening moles, sometimes within a day, a handful of melanomas, painful erections that needed surgery, muscle breakdown with kidney damage, and a brain-swelling syndrome. Case reports can't prove it caused these, and a 2017 review said a firm link to melanoma is lacking. But they're why doctors and regulators worry.

In total, only about twenty-three people have been given Melanotan II in published trials, all in small studies from the 1990s. There's no long-term safety data, and it was never approved, while its better-studied relatives were.

Melanotan II is not FDA approved. The FDA flags possible immune reactions, and published reports of melanoma, brain swelling, toxic reactions and priapism. Australia's regulator found the amount in bottles varied widely, and warns it's illegal to supply without a prescription. Agencies in the UK, Denmark and Norway have warned against it too. And it's on the agenda for the FDA's next compounding advisory meeting.

Is Melanotan II a safe way to tan? Not supported: the human data are tiny, and serious harms appear in case reports. Does it protect against sunburn or skin cancer? Not supported: Australia's regulator says it won't protect against UV the way sunscreen does. Does it boost erections? Limited: two small trials, and it was never approved. And does it curb appetite? Unproven: that's mostly mouse data.

The bottom line: Melanotan II does darken skin, but it also switches on receptors throughout the body. It was tested in only about two dozen people, never approved, and linked in case reports to moles, melanoma and other serious harms. For every study and source, see the Melanotan II profile on PepsRadar dot com.

Biological role or research focus

Melanocortin-related pigmentation research.

Melanotan I and Melanotan II are different compounds. A seller listing of one is not a source for the other.

Role reference: Human studies with Melanotan II · Int J Impot Res 2000 ↗

Names you may encounter

melanotan 2 · MT-2

Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.

Class / identity
Cyclic melanocortin analogue
Main research area
Pigmentation research
Evidence featured
Human phase 1 pilot
Source check
October 4, 2026

Source: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. ↗

Quick answers

Is Melanotan II FDA approved?
No. No FDA-approved drug contains Melanotan II. Source ↗
Is Melanotan II safe?
Unapproved tanning peptide. Tiny early trials reported nausea and spontaneous erections, and case reports describe mole changes, melanoma, priapism, rhabdomyolysis and other serious harms. Human safety data: trials only. The Risks & interactions section below lists what is known. Read the risks ↓
Is Melanotan II banned in sport?
Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
Has the FDA taken action over Melanotan II?
Yes. Our records list 2 FDA actions naming it, most recently on April 15, 2026: FDA listed Melanotan II among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Source ↗

What does the evidence show?

Evidence map

Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.

3 Human research1 Other evidence
StudyTypePopulation / model
Early pigmentation study (1996)Human phase 1 pilotThree healthy male volunteers.
Melanotan II · psychogenic erectile dysfunction (1998)Human controlled trial10 men with psychogenic erectile dysfunction.
Melanotan II · organic erectile dysfunction (2000)Human randomized trial10 men with organic erectile dysfunction.
Review · risks of unregulated use (2017)Review of case reportsPublished case reports and series of people using unregulated alpha-MSH analogues.

Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.

Human phase 1 pilot · 1996

Early pigmentation study

Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study.

Population / model
Three healthy male volunteers.
Study design
Single-blind pilot with alternating saline and active exposure.
Main finding
Pigmentation increased in two participants. Nausea, fatigue/somnolence, and prolonged spontaneous erections were reported.
Limits & context
Three volunteers cannot establish uncommon risks or durable safety. Pigmentation is not evidence of protection against ultraviolet injury or skin cancer.

Source: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. ↗

Human controlled trial · 1998

Melanotan II · psychogenic erectile dysfunction

Did Melanotan II produce erections in men with psychogenic erectile dysfunction?

Population / model
10 men with psychogenic erectile dysfunction.
Study design
Double-blind, placebo-controlled crossover study.
Main finding
Most men had erections after Melanotan II. Nausea, yawning and reduced appetite were more common than with placebo.
Limits & context
Ten participants and short follow-up. It was never developed into an approved treatment.

Source: Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. ↗

Human randomized trial · 2000

Melanotan II · organic erectile dysfunction

Did Melanotan II work in men with physical causes of erectile dysfunction?

Population / model
10 men with organic erectile dysfunction.
Study design
Double-blind, placebo-controlled crossover study.
Main finding
Erections followed 12 of 19 Melanotan II injections compared with 1 of 21 placebo injections. Severe nausea followed 4 of 19 Melanotan II injections.
Limits & context
Very small and short. Side effects were common, and the drug was not approved.

Source: Effect of an alpha-melanocyte stimulating hormone analog on penile erection and sexual desire in men with organic erectile dysfunction. ↗

Review of case reports · 2017

Review · risks of unregulated use

What harms have been reported with unregulated melanotan use?

Population / model
Published case reports and series of people using unregulated alpha-MSH analogues.
Study design
Narrative review of reported adverse effects.
Main finding
Reported problems include new and changing moles and several melanoma cases; the authors noted that conclusive evidence linking melanotan to melanoma is lacking.
Limits & context
Case reports show events in time, not cause. Unregulated products also vary in content.

Source: Risks of unregulated use of alpha-melanocyte-stimulating hormone analogues: a review. ↗

Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.

Registered human trials

1 registered study names Melanotan II as an intervention; 0 are recruiting or under way, 0 have not started recruiting yet, 0 completed and 1 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.

StudyStatusPhaseStartPeople
Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers (MT-2)
NCT04073433 · Resilient Pharmaceuticals
WithdrawnPhase 12024-120

A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination.

Further reading · 4 additional publication links

Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.

Melanotan-II reverses memory impairment induced by a short-term HF diet. ↗
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023 Sep · Journal Article

Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. ↗
Dermatology (Basel, Switzerland) · 2021 · Journal Article

CLIPSing Melanotan-II to Discover Multiple Functionally Selective hMCR Agonists. ↗
Journal of medicinal chemistry · 2022 Mar 10 · Journal Article, Research Support, Non-U.S. Gov't

Melanotan II overdose associated with priapism. ↗
Clinical toxicology (Philadelphia, Pa.) · 2013 May · Letter, Comment

Repeat this PubMed search ↗
Search additional PubMed records ↗

Risks & interactions

Unapproved tanning peptide. Tiny early trials reported nausea and spontaneous erections, and case reports describe mole changes, melanoma, priapism, rhabdomyolysis and other serious harms.

Human safety data: Trials only

Human data are a three-person pilot study, small erectile-dysfunction trials from the 1990s and 2000s, and case reports. No trial was large or long enough to measure cancer risk. Products sold online are unregulated and their contents can vary.

Take extra care with: Heart or blood pressure problemsKidney problems

It isn't approved, so there is no official list of who should avoid it, and its human studies are too small to show who is most at risk. These tags come only from the studies and warnings summarized below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.

Who should not use it

There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.

Interactions

  • Sunbeds or heavy UV exposure: several melanoma case reports involved melanotan use together with sunbed tanning

Serious risks

  • New, changing or atypical moles (eruptive nevi) in multiple case reports
  • Melanoma reported during or soon after use in case reports; a causal link is not proven
  • Prolonged painful erection (priapism), cited by FDA from published case reports
  • Muscle breakdown (rhabdomyolysis) with kidney injury and a racing heart in a case report
  • Brain swelling syndrome (PRES) and a stimulant-like toxic reaction, cited by FDA
  • Kidney infarction (blocked kidney blood flow) in a case report

Side effects reported in studies

  • nausea
  • yawning and stretching
  • spontaneous erections
  • fatigue or drowsiness
  • darkening of skin and moles

Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: FDA: Bulk drug substances that may present significant safety risks ↗ · Melanotan-II pilot phase 1 study (Life Sci, 1996) ↗ · Melanotan II injection resulting in systemic toxicity and rhabdomyolysis (case report) ↗ · Risks of unregulated use of alpha-MSH analogues: a review ↗ · Melanotan II: a possible cause of renal infarction (case report) ↗

Safety evidence & remaining uncertainty

FDA cites serious adverse-event case reports. Nausea and prolonged erections also appeared in early research; tiny trials cannot establish uncommon-event risk.

Source: FDA · Peptide compounding safety concerns ↗

Reported harms and regulator warnings

FDA's compounding safety page cites a risk of immune reactions and published reports of melanoma, a brain-swelling syndrome (PRES), toxic reactions and priapism. Australia's TGA found the amount of Melanotan II varied widely between bottles of the same product and warns it is illegal to supply without a prescription; UK and Danish regulators have also warned against it.

Source: FDA · Bulk substances that may present significant safety risks ↗

FDA compounding review

FDA has listed Melanotan II among five substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027. No date had been set when this was checked. A committee vote is advice to FDA, and inclusion on the bulks list would not make it an approved drug.

Source: FDA · Pharmacy Compounding Advisory Committee meeting before the end of February 2027 ↗

Regulatory status

U.S. FDA approval
Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source
FDA compounding (503A bulk list)
Formerly Category 2 (FDA flagged safety risks); nominations withdrawn
Was in 503A category 2 (significant safety risks) as "Melanotan II". The nominations were withdrawn by the nominators and FDA moved it to the "nominated but withdrawn" table (page updated April 22, 2026). It is not in category 1 and is not on the 503A bulks list. FDA's listing cites published reports of melanoma, posterior reversible encephalopathy syndrome and priapism. source
World Anti-Doping Agency (2026)
Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source

FDA actions

  • FDA listed Melanotan II among five bulk substances its Pharmacy Compounding Advisory Committee will discuss for the 503A bulks list at a meeting before the end of February 2027 (date not yet set). Any committee vote is advisory. (2026-04-15) source
  • FDA warning letter to a compounding pharmacy (Tailor Made Compounding) listing Melanotan II among bulk substances that are not eligible for 503A compounding exemptions. (2020-04-01) source

Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.

This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.

Research context & status

Its relatives took different paths. Afamelanotide (Melanotan I) was approved in 2019 as Scenesse for a rare light-sensitivity disease, erythropoietic protoporphyria, and bremelanotide was approved in 2019 as Vyleesi for low sexual desire in women before menopause. Neither approval covers Melanotan II or cosmetic tanning.

Source: FDA approval letter · Scenesse (afamelanotide) 2019 ↗

New editorial updates

Loading approved updates…

New source discoveries

Links appear automatically. Unreviewed discoveries are not verified medical findings.

Loading recent discoveries…

Explore the latest source feed →

Sources & supplier listings

Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.

No verified matching catalog listing yet

We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.

Mechanism & research rationale

Melanotan II is a non-selective melanocortin receptor agonist. Acting on the MC1 receptor darkens skin; acting on MC3 and MC4 receptors affects sexual arousal and, in animal studies, appetite. Because it is not selective, tanning comes with effects such as nausea, flushing, yawning and spontaneous erections.

Source: Human studies with Melanotan II · Int J Impot Res 2000 ↗

Molecular structure

Melanotan II: 2d molecular structure. The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.⤢ Enlarge 2D
2D molecular structureThe cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.PubChem · CID 92432 ↗

Questions worth asking

  • What specific product, route, and research population does the claim refer to?
  • Does the source measure an outcome in people, or only a laboratory marker?
  • Melanotan I and Melanotan II are different compounds. A seller listing of one is not a source for the other.
  • What adverse effects, uncertainty, and conflicts of interest does the original source report?

Frequently asked questions

Does a darker skin color demonstrate UV protection?

The cited trial did not establish that outcome.

Source: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. ↗

Can a Melanotan I listing substitute for Melanotan II?

No. Different compounds need different identity and evidence checks.

Source: Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. ↗

Is Melanotan II the same as Scenesse or Vyleesi?

No. Scenesse is afamelanotide (Melanotan I), approved for erythropoietic protoporphyria, and Vyleesi is bremelanotide, approved for low sexual desire in premenopausal women. Melanotan II was never approved.

Source: FDA approval letter · Scenesse (afamelanotide) 2019 ↗

Does a tan from Melanotan II protect against sunburn or skin cancer?

That is not supported. Australia's TGA says it will not protect against UV exposure the way sunscreen does.

Source: TGA · Don't risk using tanning products containing melanotan 2025 ↗

References & editorial record

Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.

PUT THE EVIDENCE IN CONTEXT

Research guides

For research and education only. This page does not provide medical advice, diagnosis, or treatment. Research-only listings are not instructions for human use.

See something wrong on this page? Report a mistake · Corrections

MOLECULAR ATLAS

Melanotan II

Download illustration ↓Source record ↗
Melanotan II 2d molecular structure

The cited molecular record is shown. Salts, protonation, and formulation ingredients may differ from a specific product.